By Billy Candra 
Cambridge researchers have unveiled a revolutionary treatment approach that has demonstrated a 100% three-year survival rate for patients battling aggressive, inherited forms of breast cancer. This significant breakthrough, detailed in a study published today in Nature Communications, represents a potential paradigm shift in the management of early-stage breast cancers driven by inherited BRCA1 and BRCA2 gene mutations. The novel regimen, which combines chemotherapy with a targeted cancer drug before surgery, has shown unprecedented efficacy, offering renewed hope for patients facing these challenging diagnoses.
A New Frontier in Cancer Treatment
The "Partner" trial, spearheaded by Addenbrooke’s Hospital, part of Cambridge University Hospitals (CUH) NHS Foundation Trust, and the University of Cambridge, introduced a distinctive strategy. This involved administering a course of chemotherapy followed by the targeted cancer drug olaparib, prior to surgical intervention. The trial’s most compelling finding is that every single patient in the experimental arm, 100% of the 39 participants, survived the critical three-year period following surgery without relapse. This starkly contrasts with the control arm, where patients received only chemotherapy before surgery, achieving an 88% three-year survival rate, with nine of 45 patients relapsing and six succumbing to the disease.
Professor Jean Abraham, a consultant at Addenbrooke’s and Professor of Precision Breast Cancer Medicine at the University of Cambridge, who led the trial, expressed profound excitement about the results. "It is rare to have a 100% survival rate in a study like this and for these aggressive types of cancer," she stated. "We’re incredibly excited about the potential of this new approach, as it’s crucial that we find a way to treat and hopefully cure patients who are diagnosed with BRCA1 and BRCA2 related cancers."
Understanding BRCA-Mutated Cancers
Breast cancers associated with faulty copies of the BRCA1 and BRCA2 genes are notoriously difficult to treat due to their aggressive nature and propensity for early recurrence. These genes, normally responsible for repairing damaged DNA and suppressing tumor growth, become dysfunctional when mutated, significantly increasing a person’s lifetime risk of developing breast, ovarian, prostate, and pancreatic cancers. The public consciousness around BRCA mutations was significantly heightened in 2013 when actress Angelina Jolie, a BRCA1 carrier, openly discussed her preventative double mastectomy, bringing the genetic predisposition to cancer into global conversation.
Currently, the standard treatment protocol for such cancers typically involves neoadjuvant chemotherapy and sometimes immunotherapy to shrink the tumor before surgical removal. The initial three years post-surgery are considered a high-risk window, during which patients are most vulnerable to relapse or death. The Partner trial directly addressed this critical period by optimizing pre-surgical intervention.
The Innovation: Timing and Targeted Therapy
The success of the Partner trial hinges on two key innovations: the strategic integration of olaparib, a PARP inhibitor, into the neoadjuvant regimen, and the meticulous timing of its administration. Olaparib, already approved and available on the NHS for certain cancers, works by exploiting a weakness in cancer cells with faulty BRCA genes, leading to their death. It functions by inhibiting poly (ADP-ribose) polymerase (PARP) enzymes, which are crucial for DNA repair. In BRCA-deficient cells, blocking PARP leads to an accumulation of DNA damage, pushing the cells towards programmed cell death in a process known as synthetic lethality.
Crucially, the trial demonstrated the benefit of a carefully timed 48-hour "gap" between the final dose of chemotherapy and the commencement of olaparib treatment. This specific timing, proposed after a "chance conversation" between Professor Abraham and Mark O’Connor, chief scientist in Early Oncology R&D at AstraZeneca, is hypothesized to allow a patient’s bone marrow to recover from the cytotoxic effects of chemotherapy, while simultaneously leaving the tumor cells highly susceptible to the targeted action of olaparib.
Mark O’Connor elaborated on this, stating, "The Partner trial highlights the importance of detecting and treating cancer early, and the value of innovative science in informing clinical trial design, in this case using bone marrow stem cells to identify the combination gap schedule." He added, "While the findings need to be validated in a larger study, they’re incredibly exciting, and have the potential to transform outcomes for patient populations who have unmet clinical need."
A Patient’s Journey: Hope and Renewal
For patients like Jackie Van Bochoven, 59, from South Cambridgeshire, the trial’s findings translate into a tangible second chance at life. Diagnosed in February 2019 with an aggressive, albeit small, tumor, Jackie recounted her initial shock and fear. "When I had the diagnosis, I was completely shocked and numb, I thought about my children, and my mum and sister who were diagnosed with breast cancer. I was pretty worried," she shared. Six years later, Jackie is cancer-free and thriving. "Six years on, I’m well and cancer free. I’m back at work, enjoying life and spending time with my family. When you’ve had cancer, I think you look at life differently and every day is a bonus." Her experience underscores the profound impact such advancements have on individual lives, offering not just extended survival but also an improved quality of life.
Broader Implications and Future Directions
The potential ramifications of the Partner trial extend beyond breast cancer. The findings suggest that this innovative approach could be applicable to other cancers caused by faulty BRCA genes, including certain ovarian, prostate, and pancreatic cancers, which also present significant treatment challenges. The principles of optimized timing and synergistic drug combinations could pave the way for more effective therapies across a spectrum of genetically-driven malignancies.
Furthermore, the trial’s outcomes present compelling economic benefits for healthcare systems like the NHS. Currently, olaparib is often prescribed post-surgery for a duration of 12 months. In the Partner trial, patients received olaparib pre-surgery for a significantly shorter period of 12 weeks. This reduction in treatment duration, coupled with the potential for fewer relapses and subsequent complex treatments, could lead to substantial cost savings for the NHS, optimizing resource allocation while improving patient outcomes.
Michelle Mitchell, Chief Executive of Cancer Research UK, one of the trial’s funders, highlighted this aspect: "One of the best ways that we can beat cancer sooner is by making more effective use of treatments that are already available to us. While this research is still in its infancy, it is an exciting discovery that adding olaparib at a carefully-timed stage of treatment can potentially give patients with this specific type of breast cancer more time with their loved ones." She emphasized the need for further studies to confirm the safety and effectiveness of this technique for broader NHS adoption.
The Power of Collaboration: Cambridge’s Vision
The success of the Partner trial is a testament to the power of collaborative research, bringing together clinical expertise, world-class scientific inquiry, and industry innovation. This model of cooperation between NHS institutions, academia, and pharmaceutical companies embodies the vision for the Cambridge Cancer Research Hospital, a specialist facility slated for construction on the Cambridge Biomedical Campus, Europe’s leading life sciences hub. This future hospital aims to consolidate clinical expertise from Addenbrooke’s Hospital with scientists from the University of Cambridge, the Cancer Research UK Cambridge Centre, and industry partners. The goal is to accelerate the development of new diagnostics and treatments, enabling earlier cancer detection and the delivery of highly personalized, precision medicine.
The Partner trial was a joint effort, sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. It received crucial funding from Cancer Research UK and AstraZeneca, with additional support from the NIHR Cambridge Biomedical Research Centre, the Cancer Research UK Cambridge Centre, and Addenbrooke’s Charitable Trust (ACT). This extensive network of support underscores the collective commitment to advancing cancer care.
The Road Ahead: Validation and Expansion
While the initial results are exceptionally promising, Professor Abraham and her team are already planning the next crucial phase of research. This will involve a larger-scale study designed to replicate the current findings and definitively confirm that the "Partner approach" not only offers superior efficacy but also a less toxic and more cost-effective treatment option compared to the current standard of care. The journey from groundbreaking discovery to widespread clinical application is often long and rigorous, but the initial data from the Partner trial provide a robust foundation for optimism, potentially heralding a new era of personalized and highly effective treatment for patients with inherited aggressive breast cancers.
